This technology is a formulation of high concentration Pen1-XBir3, a caspase-9 inhibitor compound, for use in humans and larger animal models.
Caspases are a family of proteins that play an essential role in programmed cell death. Therefore, a caspase deficiency can result in tumor growth, while caspase overactivation can lead to neurodegenerative disease. Previous research has shown that Pen1-XBir3 can effectively inhibit caspase-9 activity in cell culture, mouse, and rat models. However, it has been challenging to formulate a high enough concentration of the Pen1-XBir3 inhibitor compound for use in larger species.
This technology is a formulation of Pen1-XBir3 that removes XBir3 self-dimers, increasing the solubility of this inhibitor to produce higher concentrations, as well as improving the ability to accurately measure its concentration. Thus, Pen1-XBir3 can be produced at appropriate concentrations to inhibit caspase-9 in larger animal models and humans. This will allow for the study of caspase-9 inhibition in animal models and for the therapeutic use of Pen1-XBir3 to treat a variety of human diseases.
IR CU19412
Licensing Contact: Jerry Kokoshka